Selkirk Pharma Launches ClinFAST to Cut Fill/Finish Delays for Clinical Trials

• Selkirk Pharma has launched ClinFAST, a new service designed to accelerate the fill/finish process for clinical trial drug supplies.

• The service addresses long-standing delays in sterile manufacturing, particularly for small-batch projects often deprioritized by larger contract manufacturing organisations (CMOs).

Selkirk Pharma, a U.S.-based pharmaceutical manufacturer specialising in the fill and finish of injectable drugs, has announced the launch of ClinFAST. The service is designed to help clinical-stage biotech and pharmaceutical companies secure rapid fill/finish capacity, reducing production timelines without compromising quality.

The fill/finish process, a critical step in drug manufacturing, often presents delays ranging from six to twelve months, especially for small-volume projects. ClinFAST mitigates these delays by leveraging a templated production approach, parallel processing, and on-site inventory of key materials such as ISO-sized vials, stoppers, and excipients. The company also offers flexibility for clients to integrate their own materials within the ClinFAST framework.

“In clinical drug development, time is everything. Delays in sterile fill/finish can mean missed trial milestones and significant financial setbacks,” said Colleen Dixon, CEO of Selkirk Pharma. “ClinFAST represents a significant advancement in our ability to ensure biotech and pharma companies can access the high-quality drug product manufacturing they need—without the typical wait times.”

Key features of ClinFAST include rapid turnaround times, batch sizes up to 10,000 vials, high-yield processing to minimise production losses, and scalability to support clients beyond clinical trials. By offering this dedicated solution, Selkirk Pharma aims to help drug developers meet critical clinical timelines in an increasingly constrained contract manufacturing landscape.